Goldman: Biopharma Valuation Discount Hits Extreme Lows; Key Near-Term Catalysts In Focus

Stock volatility across the pharmaceutical sector remains elevated, driven by a flurry of high-impact developments—just in the past week alone:

1. Trump Targets Big Pharma: Slashes Drug Prices With 'Most Favored Nation' Rule, Aims To Cut Out Middlemen

2. UnitedHealth Group Slams "Deeply Irresponsible" WSJ Report As Shares Suffer Worst Weekly Crash Since 1998

3. Novo Nordisk CEO To Step Down Following Brutal Bear Market

These combined market-driven events have pushed sentiment and valuations to extremely low levels.